ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.69
+0.34 (1.40%)
Dec 5, 2025, 4:00 PM EST - Market closed
ArriVent BioPharma Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for ArriVent BioPharma stock ranges from a low of $31 to a high of $45. The average analyst price target of $38.56 forecasts a 56.18% increase in the stock price over the next year.
Price Target: $38.56 (+56.18%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $43 | Strong Buy | Initiates | $43 | +74.16% | Nov 25, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $33 → $31 | Strong Buy | Maintains | $33 → $31 | +25.56% | Nov 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +70.11% | Aug 12, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $40 → $33 | Strong Buy | Maintains | $40 → $33 | +33.66% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +62.01% | Jul 22, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
535.50K
EPS This Year
-4.38
from -2.56
EPS Next Year
-3.96
from -4.38
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 4.4M | ||||
| Avg | n/a | 535,500 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.24 | -2.90 | ||||
| Avg | -4.38 | -3.96 | ||||
| Low | -4.35 | -5.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.